Ticker brief
ELVN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
3
crowd 14d
-0.0σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-12 · now +0.05 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PrismMarketView | C | · | 2 | +0.15 |
| @PrismDM | A | -2.76 | 2 | +0.28 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-12 | @PrismDM | +0.05 | Surveys five clinical-stage metastatic breast-cancer programs while emphasizing early data and binary risks. | · | tweet ↗ |
| 2026-10-12 | @PrismMarketView | +0.05 | Presents a basket of metastatic-breast-cancer biotechs and their clinical programs while stressing binary risks. | · | tweet ↗ |
| 2026-10-08 | @Quantumup1 | +0.40 | Guggenheim reiterated Buy and a $78 target after FDA alignment on Phase 3 design. | · | tweet ↗ |
| 2026-10-07 | @PrismDM | +0.50 | Enliven reaches FDA alignment on a Phase 3 trial design and targets a start before year-end. | · | tweet ↗ |
| 2026-10-07 | @PrismMarketView | +0.25 | Enliven aligned with the FDA on its pivotal Phase 3 trial design and plans a 2026 start. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.